Sökning: onr:"swepub:oai:DiVA.org:uu-56156" >
Positron emission t...
Positron emission tomography 11C-methionine and survival in patients with low-grade gliomas
-
- Ribom, Dan (författare)
- Uppsala universitet,Neurologi
-
- Eriksson, Anders (författare)
- Uppsala universitet,Neurologi
-
- Hartman, Magdalena (författare)
- Uppsala universitet,Institutionen för genetik och patologi
-
visa fler...
-
- Engler, Henry (författare)
- Uppsala University Positron Emission Tomography Center, University Hospital, Uppsala, Sweden
-
- Nilsson, Anna (författare)
- Uppsala University Positron Emission Tomography Center, University Hospital, Uppsala, Sweden
-
- Långstrom, Bengt (författare)
- Uppsala University Positron Emission Tomography Center, University Hospital, Uppsala, Sweden
-
- Bolander, Hans (författare)
- Uppsala universitet,Neurokirurgi
-
- Bergstrom, Mats (författare)
- Uppsala University Positron Emission Tomography Center, University Hospital, Uppsala, Sweden
-
- Smits, Anja (författare)
- Uppsala universitet,Neurologi
-
visa färre...
-
(creator_code:org_t)
- 2001
- 2001
- Engelska.
-
Ingår i: Cancer. - 0008-543X .- 1097-0142. ; 92:6, s. 1541-1549
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUNDConsiderable numbers of patients with low-grade gliomas experience an early malignant course and may benefit from aggressive treatment. These patients are difficult to identify using established prognostic factors. A retrospective study was performed to determine whether the 11C-methionine uptake in tumor is a survival factor in adult patients with supratentorial gliomas classified as World Health Organization Grade 2.METHODSThe authors identified 89 patients with histologically confirmed low-grade gliomas in whom an 11C-methionine positron emission tomography (PET) scan had been performed as part of the diagnostic tumor investigation from 1983 to 1998. Clinical data were collected, and the PET scans were re-evaluated according to a fixed protocol. The 11C-methionine uptake in the tumor and relevant clinical parameters were entered into univariate and multivariate survival analyses.RESULTSAt the end of the study, 49 patients (55.1%) had died. The median overall survival was 5.7 years. Low methionine uptake was significantly favorable in the multivariate survival analysis (P = 0.04) along with oligodendroglioma (P = 0.003). In the histologic subgroups, 11C-methionine uptake was an important survival factor among patients with astrocytomas (P = 0.05) and oligodendrogliomas (P = 0.03). Tumor resection was a favorable prognostic factor in patients with high methionine uptake (P = 0.01) but not in patients with low uptake.CONCLUSIONSBaseline 11C-methionine PET is a prognostic indicator in patients with low-grade gliomas. The results imply that PET is a valuable tool in the clinical management of these patients and may assist in the selection of patients for therapy.
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
-
Cancer
(Sök värdpublikationen i LIBRIS)
Till lärosätets databas